Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer
OncLive,
Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type…
VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent…
Overview of attention for article published in Annals of Oncology, April 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (75th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 11 Mendeley